Investor Overview

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has two clinical stage oncology candidates, RX-3117 and RX-5902 (Supinoxin™), and additional compounds in preclinical development to treat multiple types of cancer.

Shareholder Letter - August 2018

Press Releases

Date Title and Summary
Toggle Summary Washington Business Journal, Rexahn Volunteers with Habitat for Humanity
Washington Business Journal, Rexahn Volunteers with Habitat for Humanity October 6 – 12, 2006 by Lindsay Smith, Staff Who’s Giving: Rockville-based Rexahn Pharmaceuticals Who’s Receiving: Habitat for Humanity What’s Being Given: A day of carpentry Background: Habitat for Humanity’s work on a house
Toggle Summary Video: Rexahn CEO Presentation at NASDAQ Marketsite
Video: Rexahn CEO Presentation at NASDAQ Marketsite Dr. Chang Ahn Announces Phase IIa Study Results of Serdaxin in Major Depressive Disorder
Toggle Summary Utrech University Study Indicates that Rexahn’s Zoraxel Could Become New-Class of Drug for Treating Sexual Dysfunction
More evidence suggests Zoraxel as potential treatment for drug related and non-drug related sexual dysfunction

Events & Presentations

Date Event Details
Summary Toggle Oct 2 - Oct 3, 2018
Title:  RX-3117, A NOVEL, ORAL NUCLEOSIDE ANALOG, IN COMBINATION WITH NAB-PACLITAXEL (NAB-PAC) IN FIRST-LINE METASTATIC PANCREATIC CANCER (MET-PC): SAFETY, TOLERABILITY AND PRELIMINARY RESPONSES   [View Poster]

Location

National Institutes of Health in Bethesda, Maryland
Summary Toggle Sep 6, 2018
9:35 AM EDT
Sep 6, 2018 9:35 AM EDT 09/06/18
Summary Toggle Jun 1-5, 2018 Jun 1 - Jun 5, 2018 12:00 AM EDT 06/01/18

Title:   Preliminary Results From an Ongoing Phase 2a Study of RX, an Oral Nucleoside Analogue to Treat Advanced Urothelial Cancer (aUC)  [View Poster]

Title:  Preliminary Report of A Phase 1b/2a Trial, An Oral Inhibitor of Phosphorylated P68 (P-p68),  Which Mediates β-catenin Nuclear Translocation in Advanced Triple-Negative Breast Cancer (TNBC)    [View Poster]



©2018 by Rexahn Pharmaceuticals, Inc. All rights reserved
Rexahn Pharmaceuticals, Inc. - 15245 Shady Grove Road, Suite 455 - Rockville, MD 20850

Terms of Use
Privacy Policy